Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Ionis Announces the Appointment of Two New Board Members
-
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
-
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
-
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
-
Ionis Pharma (IONS), Akcea Therapeutics (AKCA) Partner on Inotersen for hATTR; $150M Upfront to Ionis Paid in Stock
-
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Pre-Open Movers 02/27: (LPCN) (MNK) (DDS) Higher; (AKRX) (NTRI) (AKCA) Lower (more...)
-
Cowen Downgrades Akcea Therapeutics, Inc. (AKCA) to Market Perform
-
Cowen Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
-
Akcea Therapeutics (AKCA) Closes IPO, Reports $50M Private Placement with Novartis Pharma (NVS)
-
Akcea Therapeutics Announces Closing of Initial Public Offering
-
Akcea Therapeutics (AKCA) IPO Opens Modesty Higher
-
Akcea Therapeutics (AKCA) Prices 15.625M Share IPO at $8/Sh
-
Akcea Therapeutics Announces Pricing of Initial Public Offering
-
Akcea Therapeutics (AKCA) Launches Proposed IPO with Initial Offering Price of $12 to $14/Share (IONS)
-
Akcea Therapeutics Launches Proposed Initial Public Offering
-
Ionis Pharma (IONS) Spinoff Akcea Therapeutics (AKCA) Files IPO
-
Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering